Last updated: February 17, 2026
Market Analysis and Price Projections for NDC 42291-0310
Overview
NDC 42291-0310 is the marketed formulation of Blenrep (belantamab mafodotin-blmf), a monoclonal antibody-drug conjugate (ADC) approved via accelerated pathways for relapsed or refractory multiple myeloma. Since its approval by the FDA in August 2020, Blenrep has established a niche in the multiple myeloma treatment landscape, competing primarily with existing therapies like carfilzomib, pomalidomide, and daratumumab.
Current Market Landscape
Indications and Usage
-
Approved for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
-
The therapy is administered intravenously, with dosing based on weight and following specific schedules.
Market Size and Trends
-
Multiple myeloma incidence in the U.S. is approximately 34,000 new cases annually (per American Cancer Society).
-
The global multiple myeloma therapeutics market is projected to reach $15.5 billion by 2025, with ADCs capturing an increasing share due to targeted efficacy.
-
The U.S. market for later-line multiple myeloma treatments is estimated at $3.2 billion currently (IQVIA, 2022).
-
Blenrep's market penetration has remained incremental due to competition and safety concerns, especially keratopathy observed as an adverse effect leading to dose modifications.
Pricing Analysis
Current Pricing
-
The wholesale acquisition cost (WAC) for Blenrep: approximately $13,300 per 50 mg vial as of late 2022 (Red Book, 2022).
-
Typical dosing: 2.5 mg/kg every three weeks, with most patients receiving 30–50 mg per dose.
-
Estimated average treatment cycles per patient: 4–6, which translates to $53,200–$79,800 per patient over a treatment course.
Price Trends
-
The price has remained relatively stable since launch, with marginal adjustments for inflation and packaging costs.
-
Price competition from other therapies, especially CAR-T options like idecabtagene vicleucel and belantamab mafodotin biosimilar candidates (though biosimilar entry is limited), exerts downward pressure.
-
Payer negotiations and utilization management may further impact real-world prices.
Competitive Landscape and Future Price Projections
Key Competitors
-
Darzalex (daratumumab): $7,800 per dose, administered weekly or biweekly; more established with broader indications.
-
Revs like CAR-T therapies: Real-world costs exceed $400,000 per treatment, but offer durable responses in select patients.
-
Emerging ADCs and biosimilars: Potentially lower-cost alternatives, though biosimilar versions of belantamab mafodotin are currently lacking.
Possible Price Trajectory (Next 3–5 Years)
| Scenario |
Assumption |
Price Range per 50 mg vial |
Rationale |
| Status Quo |
No significant patent challenges; stable sales |
$13,300–$14,000 |
Market maintains current pricing with gradual inflation; limited biosimilar emergence. |
| Moderate Downward |
Entry of biosimilar candidates or increased competition |
$10,000–$12,000 |
Biosimilar competition could erode market share and pressure prices downward. |
| Accelerated Decline |
Policy pressures, payer restrictions, or safety concerns limit use |
<$10,000 |
Major policy shifts or safety issues lead to significant reimbursement pressure and volume decline. |
Impact Factors and Trends
-
Regulatory and safety profile: Ocular toxicity remains a concern; ongoing management strategies could influence physician prescribing habits.
-
Market penetration: Currently modest, with room for growth in earlier lines if safety and efficacy are demonstrated in future trials.
-
Patent protections: Likely resistant to biosimilar competition until late 2020s, providing some price stability in the short term.
-
Reimbursement landscape: Payers scrutinize the high costs with increasing demand for value-based arrangements; outcomes-based contracting may influence net prices.
Key Takeaways
-
NDC 42291-0310 (Blenrep) remains a niche, high-cost therapy for heavily pretreated relapsed or refractory multiple myeloma.
-
Current per-vial pricing holds steady but faces headwinds from biosimilar development, market competition, and reimbursement pressures.
-
Price projections suggest stability in the near term, with a potential decline of 15–30% over 3–5 years if biosimilar or alternative therapies gain market share.
-
Market growth is contingent on safety profile management, expanding indications, and competitive positioning within the evolving multiple myeloma therapeutic landscape.
-
Broader market dynamics, including rising drug prices and payer cost controls, will influence overall pricing trims and market share.
FAQs
1. How does Blenrep's pricing compare to other multiple myeloma therapies?
Blenrep’s per-vial cost (~$13,300) exceeds many standard monoclonal antibodies like daratumumab (~$7,800 per dose). However, CAR-T therapies are significantly more expensive but are used in different treatment settings.
2. What factors could lead to a significant price reduction for Blenrep?
Introduction of biosimilar versions, safety concerns limiting use, or policy changes favoring cost-effective therapies could reduce prices.
3. How do safety issues impact market penetration?
Keratopathy and other ocular toxicities necessitate dose adjustments and monitoring, potentially limiting utilization, especially outside specialized centers.
4. What role will biosimilars play in the future price landscape?
Biosimilar options could reduce list prices by 15–30%, especially in markets where biosimilar approved versions are introduced.
5. Can emerging therapies displace Blenrep?
Yes. Therapies like CAR-T cells or novel ADCs with better safety or efficacy profiles could diminish Blenrep’s market share, impacting pricing and revenue.
References
- American Cancer Society. "Myeloma." 2022.
- IQVIA. "Global Oncology Market Reports." 2022.
- Red Book. "Drug Pricing Data." 2022.
